1

CURRICULUM VITAE

Edward H. Giannini

Place of Birth, Citizenship: Chicago, Illinois, U.S.A. Education: B.S. Microbiology, 1970; University of Arizona, Tucson, and Arizona State University, Tempe, Arizona M.Sc. Immunology, 1973; Arizona State University, Tempe, Arizona Dr.P.H. (Doctor of Public Health) Epidemiology/Biostatistics, 1978, University of Texas Health Science

Center at Houston, School of Public Health Post-Doc Fellowship:

1976- 83 & Faculty Res Assoc; Dept Peds, Div of Rheumatology, Baylor College of Medicine, Texas Childrens Hosp., Houston, Texas

Education Related Honors, Awards, and Scholarships 1966-67 Freshman class vice president 1967-68 Sophomore class president 1967-68 Sigma Delta Phi fraternity president 1967-68 AiResearch Corporation Science Scholarship 1970-73 Graduate teaching assistant in immuno/micro; Ariz State Univ 1971-72 NIH general purpose fellowship in immunology; Ariz State Univ 1975-78 NIH general purpose traineeship in public health at Univ TX, Houston Medical and Medically Related Employment 1973-75 Director; Antivenin Production Laboratory, State of Arizona 1973-75 Staff Instructor in Immuno/Micro; Ariz State Univ 1975-78 Research Data Analyst; Dept Immuno/Micro; Baylor College Med 1978-81 Director; Program in Institutional Infection Control Practice; Univ Texas School of Public Health 1978-81 Adjunct Asst Prof, Dept of Science, Univ Houston Downtown 1978-83 Post-Doc Faculty Research Associate; Dept Pediatrics, Baylor College Med 1983-89 Assistant Prof, Dept Pediatrics, Baylor College of Medicine 1987-89 Adjunct Assoc. Professor, Texas Woman's University, Sch. of Physical Therapy. 1990-93 Associate Prof, Dept of Pediatrics, Univ Cincinnati College of Medicine. 1993 - Tenured Professor of Pediatrics; Division of Rheumatology, Children's Hospital Medical Center, Dept Pediatrics, Univ. Cincinnati College of Medicine.

2

Advisory/Consultant/Reviewer/Editorial Board Positions/Academic Societies’ Membership NIH National Library of Medicine Biomedical Review Committee NIH Advisor to the Division of Research Resources for the CLINFO Project NIH Advisor to the Biotechnology Resources Program NIH ad-hoc Advisory Committee for Clinical Trials NIH Reviewer: General Clinical Research Center program NIH Reviewer: NIAMS MAMDC program NIH ad-hoc study section, NIAMS MCRC program NIH, NIAMS, Data Base Research Committee Methodist Hospital, Houston - Scientific Advisory Committee, GCRC. American College of Rheumatology, Clinical Trials Committee American College of Rheumatology, Journal Publications Committee American College of Rheumatology, Subcommittee on Clinical Research, and

Chairman, ad-hoc Committee on Clinical Research Education FDA ad-hoc Committee to revise the Guidelines for the Study of Antirheumatic and Anti- inflammatory Agents in Children (Chairman) Trustee Grants Study Section (Clinical Effectiveness); Information Services Faculty Advisory Committee Arthritis Foundation Grants Review Study Section Reviewer (5 or more manuscripts per year) for Arthritis and Rheumatism, Arthritis Care and Research, Journal of

Rheumatology, Annals of Rheumatic Diseases (UK) Publications Committees: Arthritis and Rheumatism; and Joint Committee for the Publication of Arthritis and

Rheumatism and Arthritis Care and Research 1997 - 1999 Elected Member: Society for Pediatric Research/American Pediatric Society. Recipient of the 2002 Arthritis Foundation’s Virginia P Engalitcheff Award for Impact on Quality of Life of Persons

with Arthritis. American College of Rheumatology Committee on Research (pediatric representative) 2002 - 2006 American College of Rheumatology Committee on Quality Measures (Committee on Research, pediatric

representative) 2004 – 2006 American College of Rheumatology Impact of Arthritis Taskforce 2005 – 2006 Cincinnati Children’s Hospital Medical Center Conflict of Interest Committee 2001-2005 Cincinnati Children’s Hospital Medical Center: GCRC Scientific Advisory Committee 1997 - 2009 Cincinnati Children’s Hospital Medical Center, Committee on AAHRPP accreditation Cincinnati Children’s Hospital Medical Center, Chairman; TEEN-Labs Bariatric Surgery in Obese Adolescents Data Management Advisory Board; 2008-2009 Cincinnati Children’s Hospital Medical Center, Data Management Center committee member 2009-present Scientific Director, Pediatric Rheumatology Collaborative Study Group 30th Anniversary in 2006 Co-Director, International Coordinating Center of the Pediatric Rheumatology Collaborative Study Group (PRCSG) Network 2006-present Chairman of the Scientific Advisory Board to CARRA-Rx; 2010 - 2012 The Myositis Association (TMA): Grant review study section. 2012

3

PUBLICATIONS Peer Reviewed Professional Journal Articles: Giannini EH, Northey WT, Leathers CR: The allergic significance of certain fungi rarely reported as allergens. Annals of Allergy 1975; 35:372-376. Giannini EH, Holguin AH, Cada R: Infection control practitioners: Their duties, opinions, and characteristics within the state of Texas. Texas Hospitals 1978; 35:34-35. Brewer EJ, Giannini EH, Barkley E: Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis and Rheumatism 1980; 23:404-411. Brewer EJ, Giannini EH, Rossen RD, Patten B, Barkley E: Plasma exchange of a childhood onset dermatomyositis patient. Arthritis and Rheumatism 1980; 23:509-513. Brewer EJ, Nickeson RW, Rossen RD, Person DA, Giannini EH, Milam JD: Plasma exchange in selected patients with juvenile rheumatoid arthritis. Journal of Pediatrics 1981; 98:194-200. Brewer EJ, Giannini EH, Baum J, Cassidy JT, Fink CW, Hanson V, Jacobs JC, Schaller JG: Sodium meclofenamate in the treatment of juvenile rheumatoid arthritis: Journal of Rheumatology 1982; 9:129-134. Brewer EJ, Giannini EH, Baum J, Fink CW, Hanson V, Jacobs JC, Schaller JG: Proquazone in the treatment of juvenile rheumatoid arthritis: a segment I study. Journal of Rheumatology 1982; 9:135-139. Bass JC, Giannini EH, Brewer EJ, Athreya B, Brandstrup NE, Goldsmith DP, Miller JJ, Pachman LM: Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis: a segment I study. Journal of Rheumatology 1982; 9:140-143. Brewer EJ, Giannini EH, Baum J, Bernstein B, Fink CW, Schaller JG, Knee CM: Ketoprofen (Orudis) in the treatment of juvenile rheumatoid arthritis: a segment I study. Journal of Rheumatology 1982; 9:144-148. Brewer EJ, Giannini EH, Baum J, Bernstein B, Fink CW, Emery HM, Schaller JG: Aspirin (ASA) and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis: Results of the double-blind trial. Journal of Rheumatology 1982; 9:123-128. Brewer EJ, Giannini EH: Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. I. Design. Journal of Rheumatology 1982; 9:109-13 Giannini EH, Brewer EJ: Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. II. Analysis and presentation of data. Journal of Rheumatology 1982; 9:114-122. Rossen RD, Crane MM, Morgan AC, Giannini EH, Giovanella BC, Towmey JJ, Hersh EM: Circulating immune complexes and tumor cell cytotoxins as prognostic indicators of malignant melanoma. A prospective study of 53 patients. Cancer Research 1983; 43:422-429.

4

Giannini EH, Brewer EJ, Person DA: Auranofin in the treatment of juvenile rheumatoid arthritis. Journal of Pediatrics 1983; 102:138-141. Giannini EH, Person DA, Brewer EJ, Parks DB: Blood and serum concentrations of gold after a single dose of auranofin in children with juvenile rheumatoid arthritis (JRA). Journal of Rheumatology 1983; 10:496-498. Brewer EJ, Giannini EH, Person DA: Early experiences with auranofin in juvenile rheumatoid arthritis. American Journal of Medicine 1983; 75:152-156. Giannini EH, Brewer EJ, Person DA: Blood gold concentrations in children with juvenile rheumatoid arthritis (JRA) undergoing long-term oral gold (auranofin) therapy. Annals of Rheumatic Disease 1984; 43:228-231. Giannini EH, Stillman CM, Brewer EJ: Measurement of grip strength in children using the martin vigorimeter and adapted sphygmomanometer cuff. Occupational Therapy Journal of Research 1984; 4:234-236. Lovell DJ, Giannini EH, Brewer EJ: Time course of response of non-steroidal anti-inflammatory drugs in juvenile rheumatoid arthritis. Arthritis and Rheumatism 1984; 27:1433-1437. Bass JC, Athreya BH, Brewer EJ, Giannini EH, et al: A once-daily antiinflammatory drug, oxaprozin, in the treatment of juvenile rheumatoid arthritis. Journal of Rheumatology 1985; 12:384-386. Rossen RD, Swain JL, Michael LH, Weakley S, Giannini EH, Entman ML: Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle: a possible initiator of an extra myocardial mechanism of ischemic injury. Circulation Research 1985; 57:119-130. Gedalia A, Brewer EJ, Person DA, Giannini EH: Hypermobility of the joints in juvenile episodic arthralgia/ arthritis. Journal of Pediatrics 1985; 107:873-876. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L: D - penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of the U.S.A. - U.S.S.R. double-blind, placebo controlled trial. New England Journal of Medicine 1986; 314:1269-1276. Giannini EH, Brewer EJ, Person DA, He X: Long-term auranofin therapy in patients with juvenile rheumatoid arthritis. Journal of Rheumatology 1986; 13:768-770. Giannini EH, Brewer EJ for the Pediatric Rheumatology Collaborative Study Group: Poor correlation between the erythrocyte sedimentation rate and clinical activity in juvenile rheumatoid arthritis. Clinical Rheumatology 1987; 6:197-201. Giannini EH, Brewer EJ, Kuzmina N, Alekseev L, and Shokh BP for the Pediatric Rheumatology Collaborative Study Group: Characteristics of responders and non-responders to slow-acting anti-rheumatic drugs in juvenile rheumatoid arthritis. Arthritis and Rheumatism 1988; 31:15-20.

5

Arroyo I, Brewer EJ, Giannini EH: Arthritis/arthralgia and hypermobility of the joints in school children. Journal of Rheumatology 1988; 15:978-980. Sheerin KA, Giannini EH, Brewer EJ Jr, Barron KS: HLA B27 associated arthritis in childhood: Long-term clinical and diagnostic outcome. Arthritis and Rheumatism 1988; 31:1165-1170. Giannini EH: The N of 1 trials design in the rheumatic diseases. Arthritis Care and Research 1988; 2:109-115. DeCunto CL, Giannini, EH, Fink CW, Brewer EJ, Person DA: Prognosis among children with poststreptococcal reactive arthritis. Pediatric Infectious Disease Journal 1988; 7:683-686. Van Kerckhove C, Giannini EH, Lovell DJ: Temporal patterns of response to d-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients. Arthritis and Rheumatism 1988; 31:1252-1258. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Wallin B for the Pediatric Rheumatology Collaborative Study Group. Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the U.S.A. - U.S.S.R. double-blind, placebo controlled cooperative trial. Arthritis and Rheumatism 1990; 33:466-476. Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH, Hoyeraal HM, Bernstein B, Person DA, Fink CW, Alexander LA, Scheinbaum M for the Pediatric Rheumatology Collaborative Study Group: Liquid ibuprofen in the treatment of juvenile rheumatoid arthritis: results of the double-blind and open studies conducted by the Pediatric Rheumatology Collaborative Study Group. Journal of Pediatrics 1990; 117:645-52. Barron KS, Montalvo JF, Aaron KJ, Hilario MO, Saadeh C, Giannini EH, Orson FM. Soluble interleukin-2 receptors in children with Kawasaki syndrome. Arthritis and Rheumatism 1990; 33:1371-1377. Kuzmina NN, Brue E, Shaikov AV, Isaeva LA, Shakhbazian IE, Giannini EH, Iakovleva AA, Puodzhiunene EP, Vorontsov IM, Astrauskene DS: The evaluation of the therapeutic efficacy of auranofin in juvenile rheumatoid arthritis: Results of Soviet-American research. Terapevticheskii Arkhiv 1990; 62:38-41. Giannini EH, Barron KS, Spencer CH, Person DA, Baum J, Kredich DW, Jacobs JC, Zemel LS, Gibbas D, Passo MH, Brewer EJ: Auranofin therapy for juvenile rheumatoid arthritis: Results of the five-year open-label extension trial. Journal of Rheumatology, 1991; 18:1240-1242. Giannini EH, Malagon C, Van Kerckhove C, Taylor J, Lovell DJ, Levinson JE, Passo MH, Ginsberg J, Burke M, Glass DN: Longitudinal analysis of HLA-associated risks for iridocyclitis in juvenile rheumatoid arthritis. Journal of Rheumatology, 1991; 18:1394-1397. Maksymowych WP, Gabriel CA, Luyrink L, Melin-Aldana H, Elma M, Giannini EH, Lovell DJ, Van Kerckhove C, Leiden J, Choi E, Glass DN: Polymorphism in a T-cell receptor variable gene is associated with susceptibility to a juvenile rheumatoid arthritis subset. Immunogenetics 1992; 1768:2290-2297. Malagon C, Van Kerckhove C, Giannini EH, Taylor J, Lovell DJ, Levinson JE, Passo MH, Ginsberg J, Burke MJ, Glass DN: The iridocyclitis of early onset pauciarticular JRA: Outcome in immunogenetically characterized patients. Journal of Rheumatology 1992; 19:160-163.

6

Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS, for the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group: Methotrexate treatment of recalcitrant juvenile rheumatoid arthritis. Results of the U.S.A. - U.S.S.R. double-blind placebo-controlled trial. New England Journal of Medicine 1992; 326:1043-1049. Shaikov AV, Maximov AA, Speransky AI, Lovell DJ, Giannini EH, Solovyev SK: Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis - Preliminary results of a longterm study. Journal of Rheumatology 1992; 19:612-616. Melin-Aldana H, Giannini EH, Taylor J, Lovell DJ, Levinson JE, Passo MH, Ginsberg J, Burke MJ, Glass DN. HLA-DRB1*1104 in the chronic iridocyclitis of pauciarticular juvenile rheumatoid arthritis. Journal of Pediatrics 1992; 121:56-60. Maximov AA, Shaikov AV, Lovell DJ, Giannini EH, Soldatova SI: Chlamydia induced arthritis. Journal of Rheumatology 1992; 19:1794-1797. Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A, Kuzmina N. Comparative efficacy and safety of advanced therapy agents in juvenile rheumatoid arthritis. Seminars in Arthritis and Rheumatism 1993; 23:34-46. Henrickson M, Giannini EH, Hirsch R. Reduction of mortality and lymphadenopathy in MRL-lpr/lpr mice treated with non-mitogenic anti-CD3 monoclonal antibody Arthritis and Rheumatism 1994; 37:587-594. Pietra BA, De Inocencio J, Giannini EH, Hirsch R. The T cell immune response in Kawasaki disease. Journal of Immunology 1994; 153:1881-1888. Hughes C, Wolos JA, Giannini EH, Hirsch R. Induction of T cell anergy in an experimental model of autoimmunity using non-mitogenic anti-CD3 monoclonal antibody. Journal of Immunology, 1994; 153:3319-3325 Silverman ED, Cawkwell GD, Lovell DJ, Laxer R, Lehman T, Passo MH, Zemel L, Giannini EH for the Pediatric Rheumatology Collaborative Study Group. Intravenous immune globulin in the treatment of systemic juvenile rheumatoid arthritis: A randomized placebo-controlled trial. Journal of Rheumatology 1994; 21:2353-2358. Thompson SD, Grom AA, Bailey S, Luyrink L, Giannini EH, Murray K, Passo MH, Lovell DJ, Choi E, Glass DN. Patterns of T lymphocyte clonal expansion in HLA-typed juvenile rheumatoid arthritis patients. Journal of Rheumatology 1995; 22:1356-1364. Giannini EH, Lovell DJ, Hepburn B. FDA draft guidelines for the clinical evaluation of antiinflammatory and antirheumatic drugs in children. - Executive Summary. Arthritis and Rheumatism 1995; 38:715-718. Keenan GF, Giannini EH, Athreya BH: Clinically significant gastropathy associated with non-steroidal antiinflammatory drug use in children with juvenile rheumatoid arthrits. Journal of Rheumatology 1995; 22:1149-1151.

7

Yelin E, Callahan L, for the National Arthritis Data Work Group: The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis and Rheumatism 1995; 38:1351-1362. Ruperto N, Giannini EH: Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Annals of the Rheumatic Diseases 1996; 55:73-75. Giannini EH, Silverman ED, Lovell DJ, Sundel RP, Tague BL, Ruperto N for the Pediatric Rheumatology Collaborative Study Group. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis. A phase I/II study. Journal of Rheumatology 1996; 23:919-924. Pryhuber KG, Murray KJ, Donnelly P, Passo M, Maksymowych WP, Glass DN, Giannini EH, Colbert RA: Polymorphism in the LMP2 gene influences disease susceptibility and severity in HLA-B27 associated juvenile rheumatoid arthritis. Journal of Rheumatology 1996; 23;747-752. Murray KJ, SzerW, Grom AA, Donnelly P, Levinson JE, Giannini EH, Glass DN, Szer IS. Antibodies to the 45 kDa nuclear antigen in pauciarticular onset JRA and iridocyclitis: Selective association with MHC gene. Journal of Rheumatology 1997; 24:560-567. Ruperto N, Levinson JE, Ravelli A, Shear ES, Tague BL, Murray K, Martini A, Giannini EH. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. Journal of Rheumatology 1997; 24:945-951. Ruperto N, Ravelli A, Levinson JE, Shear ES, Murray K, Tague BL, Martini A, Glass DN, Giannini EH. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. Journal of Rheumatology 1997; 24:952-958. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism 1997; 40:1202-1209. Moroldo M, Tague BL, Glass DN, Giannini EH. Juvenile rheumatoid arthritis in affected sib – pairs. Arthritis and Rheumatism 1997; 40:1962-1966. Giannini EH, Athreya B, Cassidy JT, Ruperto N, White P for the ACR/AAP/ABP pediatric rheumatology workforce survey committee. Specialty training and distribution of effort among U.S. American College of Rheumatology members caring for children with rheumatic disease. Arthritis and Rheumatism 1997;40:2273-2274. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SP, Steen VD, Wolfe F. Prevalence estimates of arthritis and selected musculoskeletal disorders in the United States. Arthritis and Rheumatism 1998: 41:778-799. Moroldo MB, Giannini EH: Estimates of the discriminant validity of definitions of improvement for juvenile rheumatoid arthritis. Journal of Rheumatology 1998;25:986-989.

8

Moroldo MB, De Cunto C, Hübscher O, Liberatore D, Palermo R, Russo R, Giannini EH. Cross-cultural adaptation and validation of an Argentine-Spanish version of the Stanford Childhood Health Assessment Questionnaire (CHAQ). Arthritis Care and Research, 1998; 11:382-390. Yuhe M, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, Bluestone JA, Hirsch R. Inhibition of collagen induced arthritis in mice by gene therapy with viral IL-10. Journal of Immunology, 1998;161:1516-1524. Moroldo MB, Donnelly P, Saunders J, Glass DN, Giannini EH. Transmission disequilibrium as a test of linkage between pauciarticular juvenile rheumatoid arthritis and HLA. Arthritis and Rheumatism, 1998; 41:1620 – 1624. Lovell DJ, Lindsley C, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, Hicks JE, Levinson JE, Mier R, Pachman LM, Passo MH, Perez MD, Reed AM, Schikler KN, Smith M, Zemel LS, Rider LG: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The childhood myositis assessment scale (CMAS): A quantitative tool for the evaluation of muscle function. Arthritis and Rheumatism, 1999, 42:2213-2219. Murray KJ, Moroldo MB, Donnelly P, Prahalad S, Passo MH, Giannini EH, Glass DN: Age specific effects of JRA-associated HLA alleles. Arthritis and Rheumatism, 1999, 42;1843-1853. Kim K-N, Watanabe S, Ma Y, Thornton S, Leiden JM, Giannini EH, Hirsch R. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen induced arthritis following adenovirus-mediated gene transfer. Journal of Immunology; 2000;164:1576-1581 Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck B, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular-course juvenile rheumatoid arthritis. New England Journal of Medicine; 2000;342:763-769. Morris SC, Moroldo MB, Giannini EH, Orekhora T, Finkelman FD: In vivo survival of autoreactive B cells: Characterization of long-lived B cells. Journal of Immunology 2000; 164:3035-3046. Masaaki M, Morris SC, Orekhova T, Marinaro M, Giannini EH, Finkelman FD. IL-4 promotes the migration of circulating B cells to the spleen and increases splenic B cell survival. Journal of Immunology; 2000; 164:5704-5712. Prahalad S, Ryan MH, Shear ES, Thompson SD, Giannini EH, Glass DN: Juvenile rheumatoid arthritis: linkage to HLA demonstrated by allele sharing in affected sib-pairs. Arthritis and Rheumatism; 2000; 43:2335-2338. Prahalad S, Ryan MH, Shear ES, Thompson SD, Glass DN, Giannini EH: Twins concordant for juvenile rheumatoid arthritis. Arthritis and Rheumatism; 2000; 43:2611-2612. Scola MP, Imagawa T, Boivin GP, Giannini EH, Glass DN, Hirsch R, Grom AA: Expression of angiogenic factors in juvenile rheumatoid arthritis: Correlation with revascularization of human synovium engrafted into SCID mice. Arthritis and Rheumatism 2001; 44:794-801. Brunner HI, Lovell DJ, Finck BK, Giannini EH: Preliminary definition of disease flare in juvenile rheumatoid arthritis (JRA) Journal of Rheumatology 2002; 29:1058-64.

9

Prahalad S, Shear ES, Thompson SD, Giannini EH, Glass DN. Increased prevalence of familial autoimmunity in simplex and multiplex juvenile rheumatoid arthritis families. Arthritis and Rheumatism 2002; 46:1851-1856. Singh RR, Ebling FM, Kumar V, Albuquerque DA, Saxena V, Marion T, Kumar V, Giannini EH, Marion TN, Finkelman FD, Hahn BH: Induction of autoantibody production is limited in non-autoimmune mice. Journal of Immunology, 2002; 169:587-594. Thornton S, Sowders, D, Aronow B, Witte DP, Brunner HI, Giannini EH, Hirsch R. DNA microarray analysis reveals novel gene expression profiles in collagen-induced arthritis. Clinical Immunology 2002; 105:155-168. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Lange M, Finck BK, Burge DJ. Long-term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis. Arthritis and Rheumatism 2003; 48:218-226. Rider LG, Giannini EH, Harris-Love M, et al: Workshop Report: Defining clinical improvement in adult and juvenile myositis. Journal of Rheumatology 2003; 30:603-617. Brunner HI, Giannini EH: Health-related quality of life in children with rheumatic diseases. Current Opinion in Rheumatology 2003; 15:602-12. Ruperto N, Ravelli A, Murray KJ… Giannini EH, Martini A for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group. International consensus for disease activity and disease damage core sets of outcome measures for juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003; 42:1452-1459. Moroldo MB, Glass DN, Chaudhari M, Thompson SD, Shear E, Giannini EH: JRA Affected Sib-Pairs: Extent of clinical phenotype concordance. Arthritis and Rheumatism, 2004; 50:1928-1934. Rider LG, Giannini EH, Brunner H, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW for the International Myositis Assessment and Clinical Studies Group (IMACS). International consensus on preliminary definitions of improvement for adult and juvenile myositis. Arthritis & Rheumatism 2004; 50:2281-2290. Barnes MG, Aronow BJ, Luyrink LK, Moroldo MB, Pavlidis P, Passo MH, Grom AA, Hirsch R, Giannini EH, Colbert RA, Glass DN, Thompson SD. Gene expression in juvenile arthritis and spondyloarthropathy: proangiogenic ELR+ chemokine genes relate to course of arthritis. Rheumatology 2004; 43:973-979. Thompson SD, Moroldo MB, Guyer L, Ryan M, Tombragel EM, Shear ES, Prahalad S, Sudman M, Keddache MA, Brown WM, Giannini EH, Langefeld CD, Rich SS, Nichols, Glass DN. A genome wide scan for juvenile rheumatoid arthritis (JRA) in affected sib pair families provides evidence for linkage. Arthritis and Rheumatism 2004; 50:2920-30. Wallace CA, Ruperto N, Giannini EH, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology InterNational Trials Organization (PRINTO), and the Pediatric Rheumatology Collaborative

10

Study Group (PRCSG). Preliminary criteria for clinical remission for selected categories of juvenile idiopathic arthritis. Journal of Rheumatology 2004; 31:2290-2294. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filopovich AH, Grom AA. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Research and Therapy 2004; 7:R30-R36. Brunner HI, Klein-Gitelman MS, Miller MJ, Barron A, Baldwin N, Trombley M, Johnson AL, Kress A, Lovell DJ, Giannini EH. Minimal clinically important differences of the childhood health assessment questionnaire (CHAQ). Journal of Rheumatology 2005; 32: 150-161. Oddis, CV, Rider LG, Reed AM…..Giannini EH, Miller, FW. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis and Rheumatism 2005; 52; 2607-2615. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis (JIA). Arthritis and Rheumatism, 2005; 52:3554-3560. Wallace CA, Ravelli A, Giannini EH. Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis (JIA). Journal of Rheumatology 2006: 33:789-795. Ruperto N, Ravelli A, Oliverira S….Giannini EH, Martini A. The Pediatric Rheumatology International Trials Organization / American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. Arthritis Care and Research 2006; 55:355-363. Lovell, DJ, Reiff, A, Jones OY…..Giannini EH for the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis and Rheumatism 2006; 54:1987-1994. Reiff A, Lovell DJ, Adelsberg JV, Kiss MHB, Goodman S, Zavaler MF, Chen P-Y, Bolognese JA, Cavanaugh PF Jr, Reicin AS, Giannini EH: Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: A 12-week randomized controlled clinical trial with a 52 week open label extension. Journal of Rheumatology, 2006; 33:985-995. Lovell DJ, Glass DN, Ranz J.…….Giannini EH. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. Arthritis and Rheumatism 2006; 54:2235-42. Ruperto N, Ravelli A …..Martini A, Giannini EH. Cyclosporine A in juvenile arthritis. Results of the PRCSG/PRINTO phase IV post-marketing surveillance study. Clinical and Experimental Rheumatology 2006; 24:599-605. Ruperto N, Lovell DJ….Martini A, Giannini EH. A randomized trial of infliximab plus methotrexate of polyarticular course juvenile rheumatoid arthritis. Arthritis and Rheumatism 2007; 56:3096-3106. Khanna D, Lovell, DJ, Giannini E et al: Development of a provisional core set of response measures for clinical trials in systemic sclerosis. Annals of Rheumatic Disease 2008; 67(5):703-709

11

Lovell DJ, Ruperto N, Goodman S….Giannini EH, Martini A: A randomized, placebo-controlled trial of adalimumab with or without methotrexate in children with polyarticular juvenile rheumatoid arthritis. New England Journal of Medicine 2008; 359:810-820. Ruperto N, Lovell DJ, ….Giannini EH, Martini A: Efficacy and safety of abatacept in children with juvenile idiopathic arthritis: A randomized, double-blind, placebo controlled withdrawal trial. Lancet 2008; 372; 383-391 Carrasco R, Lovell DJ, Giannini EH, Henderson CJ, Huang B, Kramer S, Ranz J, Heubi J, Glass DN. Biochemical markers of bone marrow turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis. Arthritis and Rheumatism 2008; 56:3932-3940. Foeldvari I, Szer, IS, Zemel LS, Lovell DJ, Giannini EH, Robbins JL, West CR, Steidle G, Krishnaswami S, Bloom BJ: Results of a prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. Journal of Rheumatology 2009; 36:174-182. Khanna D, Distler O, Avouac J…Giannini EH….Furst D. Measures of response in clinical trials of systemic sclerosis: the combined response index for systemic sclerosis (CRISS) and outcome measures in PAH related to systemic sclerosis (EPOSS). Journal of Rheumatology 2009; 36(10): 2356-2361. Giannini EH, et al: Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis and Rheumatism 2009; 60:2794-2804. Weinrub N…Giannini EH…for the Gaucher Disease Working Group. A validated disease severity scoring system for adults with type 1 Gaucher Disease. Genetics in Medicine 2010; 12:44-51. Huber AM, Giannini EH, Bowyer SL…Feldman BM: Protocols for the treatment of moderately severe juvenile dermatomyositis: Results of a CARRA consensus conference. Arthritis Care and Research 2010; 62:219-225 Giannini EH, Mehta AB, Milz MJ, et al: A validated disease severity scoring system for Fabry Disease. Molecular Genetics and Metabolism 2010; 99:283-290. Brunner HI, Higgins GC, Wiers K, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Klein-Gitelman MS, Giannini EH: Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus (cSLE). Arthritis Care and Research 2010; 62(3):335-344. Ruperto N, Lovell DJ, Cuttica R…Giannini EH: Long-term efficacy and safety of infliximab plus methotrexate in the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Annuals of the Rheumatic Diseases 2010;69:718-722 Rider LG, Koziol D, Giannini EH, et al: Validation of manual muscle testing and a subset of eight muscle (MMT8) for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care and Research 2010; 62(4):465-472. Ruperto N, Lovell DJ, Quartier P…Martini A, Giannini EH: Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis and Rheumatism 2010; 62:1792-1802.

12

Brunner HI, Klein-Gitelman M, Higgins GC…Giannini, EH: Towards the development of criteria for global disease flares in juvenile systemic lupus erythematosus. Arthritis Care and Research 2010; 62:811-820. Brunner HI, Higgins GC, Lapidus SK, Olson JC, Onel K, Punaro M, Klein-Gitelman MS, Ying J, Giannini EH: Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care and Research 2010; 62:950-959. Visvanathan S, … Giannini EH, Ruperto N for PRINTO and the PRCSG: The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in patients with juvenile idiopathic arthritis: analyses from a randomized placebo-controlled trial. Pediatric Rheumatol 2010; 8:24. Giannini EH, Ilowite NT, Lovell DJ et al: Effects of long-term etanercept on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis and Rheumatism 2010; 62:3259-3264. Ruperto N, Lovell DJ, Li T, Sigal L, Block A, Covucci A… Giannini EH: Abatacept treatment improves health-related quality of life, pain, sleep quality and activity participation in subjects with juvenile idiopathic arthritis. Arthritis Care and Research 2010; 62:1542-1551. Ruperto N, Pistorio A, Ravelli A….Giannini EH, Andersson Gare B, Martini A: The PRINTO criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research 2010; 62:1533-1541. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M,…Giannini EH: Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care and Research 2011, 63:10-16. Gottlieb AB, Gordon K, Giannini EH, et al: Clinical trial safety and mortality analysis in patients receiving etanercept across approved indications. Journal of Drugs in Dermatology 2011, 10(3):289-300. Wallace CA, Giannini EH, Huang B, Ruperto N for CARRA, PRCSG, and PRINTO. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care and Research, 2011; 63:929-936. Brunner HI, Mina R, Pilkington C,…Giannini EH: Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care and Research 2011; 63: 1213-1223 Wallace CA, Giannini EH, Spalding SJ, …Lovell DJ for the Childhood Arthritis and Rheumatology Research Alliance. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis and Rheumatism 2012; 64:2012-2021 Mina R, Klein-Gitelman MS, Ravelli A…Giannini EH, Brunner HI: Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care and Research 2012; 64:683-693 Hashkes PJ, Spalding SJ, Giannini EH,…Lovell DJ: Rilonacept for colchicine resistant or intolerant Familial Mediterranean Fever. Annals of Internal Medicine 2012; 157:533-541.

13

Lovell DJ, Giannini EH, Reiff AO, et al: Long-term safety and efficacy of Rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). Submitted, 2011. Ilowite NT, Sandborg CI, Feldman BM, Grom A, Schanberg LE, Giannini EH…Zemel L. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatric Rheumatology 2012; 10:31. Books, Chapters in Books, Invited Papers, Reviews, Editorials, Thesis, Dissertation, Giannini EH: Aerially disseminated fungi as allergens: Evaluation of 72 allergy patients. Thesis. Arizona State University Press, 1973. Giannini EH: A continuing educational curriculum for institutional infection control practitioners. Dissertation. University of Texas Press, 1978. Giannini EH: Editorial: Know the different uses of prospective and retrospective. Texas Hospitals 1979; 35:36-37. Giannini EH, Rossen RD: Immunologic contributions to the pathophysiology of glomerulonephritis (Chapter 1). In: The Kidney in Systemic Disease. Suki WN and Eknoyan G (eds.) New York, John Wiley and Sons Publishers, 1981, pp 3-36. Bottino J, Rossen RD, Giannini EH, Hersh EN, Gutterman JU: Serial testing for immune complexes in malignant melanoma. In: Protides of Biological Fluids. H Peeters (ed.) New York, Pergamon Press, 1979, pp 337-340. Brewer EJ, Giannini EH, Person DA: Juvenile Rheumatoid Arthritis, 2nd edition. Philadelphia, W.B. Saunders, 1982. Bass JC, Brewer EJ, Giannini EH, Athreya B, Goldsmith DP, Miller JJ, Pachman LM: A four-week multi-centered trial of pirprofen in juvenile rheumatoid arthritis. In: van der Korst JK (ed.): Pirprofen in the Treatment of Pain and Inflammation. Bern, Stuttgart, Vienna, Hans Huber Publishers, 1982, pp 52-57 Brewer EJ, Giannini EH: Juvenile rheumatoid arthritis (Chapter 11). In: Clinical Trials in the Rheumatic Diseases: Klippel JH and Decker JL (eds.), East Sussex, England, W.B. Saunders Company Ltd., 1983, pp 629-640. Giannini EH, Brewer EJ: Juvenile rheumatoid arthritis - Principles of management. World Pediatrics and Child Care 1987, 3:227-244. Melin-Aldana H, Giannini EH, Glass DN: Immunogenetics of early onset pauciarticular juvenile rheumatoid arthritis. Journal of Rheumatology 1990 (suppl 24); 18:2-6. Giannini EH, Cassidy JT. Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks? Drug Safety 1993; 9:325-339. De Inocencio J, Giannini EH, Glass DN. Can genetic markers contribute to the classification of juvenile rheumatoid arthritis? Journal of Rheumatology 1993; 20(suppl40):12-18.

14

Grom AA, Giannini EH, Glass DN. JRA and the trimolecular complex. (HLA, TCR, and antigen) Differences from rheumatoid arthritis (RA). Arthritis and Rheumatism 1994; 37:47-50. Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis: Past present and future. Pediatric Clinics of North America 1995; 42:1099-1125. De Inocencio J, Pietra B, Giannini EH, Hirsch R. Persistent immune abnormalities in Kawasaki disease after IVIG therapy. IN Kawasaki Disease. (Ed) Kato H. New York, Elsevier Science B.V., 1995, pp 232 - 236. Giannini EH: Pharmacoeconomic Analysis: Intravenous Immune Globulin in Polyarticular Juvenile Rheumatoid Arthritis. IN: Biologic Agents in Autoimmune Disease. (Eds.) Strand V, Johnson K, Simon L: Atlanta, Arthritis Foundation Publication. 1995; pp 197-199 Giannini EH: Juvenile Rheumatoid Arthritis: Proposed Index. IN: Biologic Agents in Autoimmune Disease. (Eds.) Strand V, Johnson K, Simon L: Atlanta, Arthritis Foundation Publication. 1995; pp 257-260. Giannini EH: Understanding the newest approaches to therapy of rheumatic disease: Gene therapy. Arthritis and Rheumatism 1995; 38(suppl):136. Graham TB, Giannini EH: Juvenile Rheumatoid Arthritis: Assessment. Indian Journal of Pediatrics 1996; 63:283-291. Feldman BM, Giannini EH. Editorial. Where’s the evidence? Putting clinical science into pediatric rheumatology. Journal of Rheumatology 1996; 23:1502-1504. Giannini EH, Petty RE. Chapter 61. Treatment of Juvenile Rheumatoid Arthritis. IN: Arthritis and Allied Conditions, 13th Edition. (Eds.) Koopman WJ and McCarty DJ. 1997. Baltimore, Williams & Wilkins Publishing. pp 1179 – 1196. Griffin TA, Giannini EH: Chapter 23: Juvenile Rheumatoid Arthritis. IN: Intravenous Immunoglobulins in Clinical Practice. (Eds: Lee ML, Strand V.) Philadelphia, Marcel-Dekker Publishers. 1997; pp 309 – 315. Mayes MD, Giannini EH, Pachman LM, Buyon JP, Fleckman P: Special Article. Connective tissue disease registries. Arthritis and Rheumatism, 1997; 40:1556-1559. Giannini EH. Gene therapy in the rheumatic diseases – Prospects for trials in children. The Italian Journal of Pediatrics 1998; 24:32-34. Giannini EH. Can non-fundable trials be conducted anyway? The case for open, randomized, actively-controlled trials in rheumatology. Annals of the Rheumatic Diseases 1998; 57:128-130. Glass DN, Giannini EH. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis and Rheumatism 1999; 42:2261 – 2268.

15

Brunner HI, Giannini EH: Review: Evidence-based medicine in pediatric rheumatology. Clinical and Experimental Rheumatology 2000; 18:407-414. Giannini EH, Petty RE. Chapter 65. Treatment of Juvenile Rheumatoid Arthritis. IN: Arthritis and Allied Conditions, 14th Edition. (Eds.) Koopman WJ and McCarty DJ. Baltimore, Williams & Wilkins Publishing. 2000, pp 1295 – 1310. Giannini EH. Editorial. Methotrexate: Vital new information about a middle-aged drug. Journal of Rheumatology, 2002; 29:2031-33. Giannini EH, Moroldo MB. Editorial: PRUNAPE: The medical, scientific and social importance of validating, standardizing, and culturally adapting screening tools. Archivos Argentina Pediatrics 2002; 100:357-359. Giannini EH, Brunner HI. Treatment of Juvenile Rheumatoid Arthritis. IN: Arthritis and Allied Conditions, 15th Edition. (Eds.) Koopman WJ and Moreland L. Baltimore, Lippincottt Williams & Wilkins Publishing. 2004; Chapter 62. Giannini EH for the American College of Rheumatology Committee on Research. Special Article. Summary of the Proceedings of the Institute of Medicine Workshop: Challenges facing the clinical research enterprise: The response of medical specialty and clinical research societies. How the College is addressing areas of concern. Arthritis and Rheumatism 2004 50: 3772-3775. Giannini EH. Chapter 8. Design, measurement and analysis of clinical investigations. IN: Cassidy JT; Petty RE; Laxer RM; Lindsey CB (Eds). Textbook of Pediatric Rheumatology. Fifth Edition. Ellseviers. 2005. pp 142-173. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW for the International Myositis Assessment and Clinical Studies Group. (IMACS). Special Article – Commentary. International consensus guidelines for therapeutic trials in the idiopathic inflammatory myopathies. Arthritis and Rheumatism 2005, 52:2607-2615 Moroldo MB, Giannini EH. Metodolgia de la investigacion en Reumatologia. IN: Espada G, Malagon, Rose C. (Eds). Manual Practico de Reumatologia Pediatrica. PANLAR. 2005. pp 69-88. Brunner HI, Giannini EH. Chapter 7. Trial Design, Measurement and Analysis of Clinical Investigations. IN: Cassidy JT; Petty RE; Laxer RM; Lindsey CB (Eds). Textbook of Pediatric Rheumatology. 6th Edition. Elsevier Saunders. 2010. Pp 127-156. Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell D. Is it time to move to active comparative trials in juvenile idiopathic arthritis? Arthritis and Rheumatism 2010; 62:3131-3139. Peer Reviewed Abstracts: Giannini EH, Northey WT, Leathers CR: Allergenic significance of some aerially disseminated fungi. Proceedings of the Annual Meeting of the American Society for Microbiology 1972; Abstract M195, pg 112.

16

Swain JL, Rossen RD, Weakley S, Giannini EH, Entman ML, Schwartz A: Myocardial localization of complement and leucocytes after coronary occlusion. Proceedings of the American Heart Association November, 1978. Bottino J, Rossen RD, Giannini EH: Prognostic value of measuring circulating immune complexes (CIC) serially in cancer patient's sera. Cancer Research 1978; 19:38. Giannini EH, Brewer EJ, Dresner AJ: A statistical methodology for evaluating therapeutic efficacy during a controlled trial of an anti-inflammatory agent in a rheumatic disease population. Proceedings of the Symposium on Coordinating Clinical Trials. Boston, Mass. 1979. Giannini EH, Brewer EJ: A comparative study of the epidemiologic and clinical natural histories of juvenile rheumatoid arthritis (JRA) subtypes. Proceedings of the Texas Medical Association. Houston, TX, 1980. Brewer EJ, Giannini EH: A comparative study of the epidemiologic and clinical natural histories of juvenile rheumatoid arthritis (JRA) subtypes. Arthritis and Rheumatism 1980; 23:656. Hummel JH, Giannini EH: Single subject research designs for clinical trials. Proceedings of the Symposium on Coordinating Clinical Trials. 1980. Person DA, Leatherwood CM, Brewer EJ, Giannini EH, Barron KS: Anti-eye antibody in juvenile rheumatoid arthritis. Clinical Research 1980; 28:863A. Ivey J, Brewer EJ, Giannini EH: Psychosocial functioning in children with juvenile rheumatoid arthritis (JRA). Arthritis and Rheumatism 1981; 24:100. Brewer EJ, Giannini EH, Baum J, Fink CW, Hanson V, Jacobs JC, Schaller JG: Proquazone in the treatment of juvenile rheumatoid arthritis: a segment I study. ILAR, XVth International Congress on Rheumatology Therapeutic Workshops, Communications and Panels. 1981; STP6:215. Brewer EJ, Bass JC, Giannini EH, Athreya BH, Goldsmith DP, Brandstrup N, Miller JJ, Pachman LM: Pirprofen in the treatment of juvenile rheumatoid arthritis (JRA): a segment I study. ILAR, XVth International Congress on Rheumatology Therapeutic Workshops, Communications and Panels. 1981; AT11:076. Person DA, Leatherwood CM, Buffone GJ, Giannini EH, Barron KS, Brewer EJ: Immune complexes in the sera of pediatric patients with rheumatic disease. Pediatric Research 1982; 16:229A. Barron KS, Brewer EJ, Giannini EH: Children at risk of developing ankylosing spondylitis. Arthritis and Rheumatism 1982; 25(suppl):S151. Giannini EH, Brewer EJ, Person DA: Auranofin in juvenile rheumatoid arthritis. Arthritis and Rheumatism 1982; 25(suppl):S17. Giannini EH, Brewer EJ, Person DA: Auranofin in juvenile rheumatoid arthritis. Pediatric Research 1983; 17:419.

17

Person DA, Leatherwood CM, Buffone GJ, Giannini EH, Barron KS, Brewer EJ.: Immune complexes in the sera of patients with rheumatic disease. Pediatric Research 1983; 17:418, abstract 3. Giannini EH, Brewer EJ: Cooperative multicentered clinical trial with the U.S.S.R. - Advantages and difficulties. Controlled Clinical Trials 1983; 4:151. Brewer EJ, Giannini EH, Person DA: Blood gold concentrations in children with juvenile rheumatoid arthritis (JRA) undergoing long-term oral gold (auranofin) therapy. Arthritis and Rheumatism 1983; 26(suppl):S58. Lovell DJ, Giannini EH, Brewer EJ, Person DA: Time course of response to non-steroidal anti-inflammatory drugs in patients with juvenile rheumatoid arthritis. Clinical Research 1983; 31:918A. Person DA, Buffone GJ, Leatherwood CM, Brewer EJ, Giannini EH: Serial determinations of circulating immune complexes (CIC) in the sera of children with rheumatic disease. Pediatric Research 1984; 18:306. Lovell DJ, Giannini EH, Brewer EJ, Person DA: Early clinical indicators of eventual response to non-steroidal anti-inflammatory drugs (NSAIDs) in patients with juvenile rheumatoid arthritis (JRA). Journal of Rheumatology 1984; 11:716. Hoyeraal HM, Brewer EJ, Giannini EH, Goolsbee CB, Lovell DJ, Person DA, Stillman C: Unconventional therapies in pediatric rheumatology. Scandinavian Journal of Rheumatology 1984; 53(suppl):113. Gedalia A, Person DA, Giannini EH, Brewer EJ: Joint hypermobility in juvenile episodic arthritis/arthralgia (JEA) Pediatric Research 1984, and Clinical Research 1984; 32:821A. Gedalia A, Brewer EJ, Giannini EH, Person DA: J Joint hypermobility in juvenile episodic arthritis/arthralgia (JEA). Proceedings of the XVIth International Congress of Rheumatology. Sydney, Australia. May 1985, pg 133. Giannini EH: Generalizations from multiple studies of non-steroidal anti-inflammatory drugs (NSAIDs) in children with juvenile rheumatoid arthritis (JRA). Proceedings of the XVIth International Congress of Rheumatology. Sydney, Australia. May 1985, pg 50. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L: D - penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of the double-blind, placebo controlled trial. Proceedings of the XVIth International Congress of Rheumatology. Sydney, Australia. May 1985, pg 50. He X, Giannini EH, Brewer EJ: Long-term usage of oral gold (auranofin) in the treatment of children with juvenile rheumatoid arthritis (JRA). Proceedings of the XVIth International Congress of Rheumatology. Sydney, Australia. May 1985, pg 105. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L: D - penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: Results of the double-blind, placebo controlled trial. Arthritis and Rheumatism 1985; 28(suppl):S14.

18

Jasso MS, Protas EJ, Giannini EH, Brewer EJ: Assessment of physical work capacity (PWC) in rheumatoid arthritis (JRA) patients. Arthritis and Rheumatism 1985; 28(suppl):S56. De Cunto CL, Brewer EJ, Giannini EH, Person DA: Outcome of children with post-streptococcal reactive disease not treated with antibiotic prophylaxis. Arthritis and Rheumatism 1985; 28(suppl):S24. Moore M, Moore W, Giannini EH, Brewer EJ, Long S, Sonnemaker R, Person DA: Radionuclide joint-bone scanning in children with rheumatic complaints. Arthritis and Rheumatism 1985; 28(suppl):S55. Giannini EH, Brewer EJ: Characteristics of responders (R) and non-responders (NR) to slower-acting anti-rheumatic drugs (SAARDs) in juvenile rheumatoid arthritis (JRA). Arthritis and Rheumatism 1985; 28(suppl):S56. Giannini EH, Brewer EJ, He X: Auranofin in the long-term treatment of children with juvenile rheumatoid arthritis (JRA). Clinical Research 1985; 33:919A. Giannini EH, Brewer EJ: Generalizations from multiple studies of non-steroidal antiinflammatory drugs (NSAIDs) in children with juvenile rheumatoid arthritis (JRA). Clinical Research 1985; 33:918A. Rossen RD, Reisberg MA, Michael LH, Moake JN, Weakley S, Giannini EH, Entman ML: Cardiac ischemia releases myocardial peptides which complex with the first component of complement. Federation Proceedings 1986; 45:940 abstract 4573. Jasso M, Protas E, Giannini EH, Brewer EJ: Assessment of physical work capacity in juvenile rheumatoid arthritis patients. American Physical Therapy Association Quarterly Cardiopulmonary Section. Winter 1986, pp 11-12. Jasso M, Protas EJ, Giannini EH, Brewer EJ: Physical work capacity (PWC) in juvenile rheumatoid arthritis (JRA) and healthy children. Arthritis and Rheumatism 1986; 29(suppl);S158. Jasso M, Protas EJ, Giannini EH, Brewer EJ: Physical work capacity in juvenile rheumatoid arthritis (JRA) patients and healthy children. Journal of Rheumatology 1986; 13:977. Giannini EH, Brewer EJ, Changes in the erythrocyte sedimentation rate correlate poorly with articular disease activity in JRA. Journal of Rheumatology 1986; 13:976. Brewer EJ, Giannini EH for the Pediatric Rheumatology Collaborative Study Group. Oral gold (auranofin) in juvenile rheumatoid arthritis (JRA): Results of the double-blind placebo controlled trial. Arthritis and Rheumatism 1987; 30(suppl) S31, Abstract #131. Sheerin KA, Giannini EH, Brewer EJ: HLA B27 associated arthritis in childhood; Long-term clinical and diagnostic outcome. Arthritis and Rheumatism 1988, 31(suppl):R44, Abst. #66S and Journal of Allergy and Clinical Immunology 1988; 81:218. Abst.#200. Brewer EJ, Kuzmina N, Giannini EH for the Pediatric Rheumatology Collaborative Study Group: Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo controlled trial. Arthritis and Rheumatism 1988, 31(suppl):S26. Abst.#89.

19

Fink CW, Brewer EJ, Kuzmina N, Giannini EH for the Pediatric Rheumatology Collaborative Study Group: Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo controlled trial. The 6th SEAPAL Congress of Rheumatology Proceedings, Tokyo, Japan Sept 5-10, 1988. Giannini EH, Brewer EJ, Scheinbaum ML, Alexander LA, Copp RL for the Pediatric Rheumatology Collaborative Study Group: Ibuprofen suspension in the treatment of JRA: Results of the double-blind, aspirin controlled trial. Arthritis and Rheumatism 1989, 32(suppl):R39 Abst. #32S. Giannini EH, Brewer EJ for the Pediatric Rheumatology Collaborative Study Group. Methotrexate in the treatment of recalcitrant JRA-Results of the double-blind, placebo controlled, randomized trial. Arthritis and Rheumatism 1989, 32 (suppl):S82, Abst. #67. Giannini EH, Brewer EJ, Shaikov A, Kuzmina N, Maximov A for the Pediatric Rheumatology Collaborative Study Group and Cooperative Children's Group: Low-dose methotrexate treatment of recalcitrant JRA - Results of the USA-USSR randomized controlled trial. Arthritis and Rheumatism 1991; 34(suppl):S53. Abst. #123 Giannini EH, Shaikov A, Maximov A, Kuzmina N, Brewer EJ for the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Group. Meta-analysis of antirheumatic drug trials in juvenile rheumatoid arthritis. Arthritis and Rheumatism 1991; 34(suppl):S152. Abst #C118. Maksymowych WP, Gabriel CA, Luyrink L, Melin-Aldana H, Elma M, Giannini EH, Lovell DJ, Van Kerchhove C, Leiden J, Choi E, Glass DN: T cell receptor variable gene is associated with susceptibility in selected patients with juvenile rheumatoid arthritis. Arthritis and Rheumatism 1991; 34(suppl):S39, abst #38. Melin-Aldana H, Giannini EH, Taylor J, Lovell DJ, Levinson JE, Passo MH, Ginsberg J, Burke MJ, Glass DN: HLA-DRB1*1104 in chronic iridocyclitis of early-onset pauciarticular juvenile rheumatoid arthritis (EOPA-JRA). Arthritis and Rheumatism 1991; 34(suppl):S36, Abst. #24. Giannini EH for the Pediatric Rheumatology Collaborative Study Group. Results of the auranofin long-term follow-up program (AU 109X) in children with juvenile rheumatoid arthritis. Journal of Rheumatology 1992; 19(suppl 33):114. Abst #15. Giannini EH, Malagon C, Van Kerckhove C, Taylor J, Lovell DJ, Levinson J, Passo M, Burke M, Glass DN: Actuarial analysis of iridocyclitis risk in HLA characterized early-onset pauciarticular JRA (EOPA-JRA) patients. Journal of Rheumatology 1992; 19(suppl 33):118. Abst. #39. Henrickson M, Giannini EH, Hirsch R. Anti-CD3 F(ab')2 fragments delay expansion of alpha beta+ CD4-CD8- B220+ cells in the MRL/lpr murine model of autoimmunity. Journal of Immunology 1993; 150(suppl):80-80A. Giannini EH. Newer therapies including biologics. XVIII ILAR Congress of Rheumatology. Barcelona, Spain. 1993. pg 233. Henrickson M, Giannini EH, Hirsch R. Non-mitogenic anti-CD3 monoclonal antibody (mAb) reduces autoimmunity in MRL-lpr/lpr mice. Arthritis and Rheumatism 1993; 36(suppl) S92. Abst. #319.

20

Giannini EH, Newman AJ, Fink CW for the Pediatric Rheumatology Collaborative Study Group. Low-dose methotrexate in children with JRA. Results of a post-trial, long-term follow-up program. Arthritis and Rheumatism 1993; 36(suppl) S54. Abst. #93 Silverman ED, Giannini EH, Gail Cawkwell for the Pediatric Rheumatology Collaborative Study Group. Intravenous immune globulin in systemic JRA. Results of a randomized controlled trial. Arthritis and Rheumatism 1993; 36(suppl) S59. Abst. #126. Giannini EH, Lovell DJ, Silverman ED, Sundel RP, for the Pediatric Rheumatology Collaborative Study Group. Intravenous immune globulin in polyarticular JRA. Results of a phase I/II trial. Arthritis and Rheumatism 1994; 37(suppl) S276. Abst.#700. Giannini EH, Lovell DJ, Felson DT, Goldsmith CH. Preliminary core set of outcome variables for use in JRA clinical trials. Arthritis and Rheumatism 1994; 37(suppl):S428. Abst.#1594. Giannini EH, Lovell DJ, for the Pediatric Rheumatology Collaborative Study Group. Redundancy of conventional outcome variables used in JRA clinical trials. Arthritis and Rheumatism 1994; 37(suppl):S328. Abst.#1005. Giannini EH, Lovell DJ. Inter-physician reliability estimates for conventional disease activity measures in JRA. Arthritis and Rheumatism 1994; 37(suppl):S328. Abst.#1004. Szer IS, Giannini EH, Donnelly P, Passo MH, Szer W, Glass DN. Anti-DEK antibodies in JRA: HLA associations. Arthritis and Rheumatism 1994; 37(suppl):S400. Abst.#1433. De Inocencio J, Pietra B, Giannini EH, Hirsch R. Persistent immune abnormalities in Kawasaki Disease (KD) after IVIG therapy. Arthritis and Rheumatism 1994; 37(suppl):S405. Abst.#1461. Thompson S, Grom A, Bailey S, Murray K, Giannini EH, Passo M, Lovell DJ, Choi E, Glass DN. High incidence of T cell

ociations. Arthritis and Rheumatism 1994; 37(suppl):S278. Abst.#710. Pryhuber KG, Murray KJ, Donnelly P, Passo M, Maksymowych WP, Glass DN, Giannini EH, Colbert RA: Polymorphism in the LMP2 gene influences disease susceptibility and severity in juvenile rheumatoid arthritis. Arthritis and Rheumatism 1995:38;S398. Abst. #1469. Lovell DJ, Giannini EH, Rider L, Hicks J, Smith M, Rennebohm R, Lindsley C, for the Juvenile Myositis Collaborative Study Group: Validation and rater reliability of the childhood myositis assessment scale (C-MAS). Arthritis and Rheumatism 1995; 38(suppl):S183. Abst #186. Giannini EH, Silverman ED, Lovell DJ, Sundel RP, Tague BL, Ruperto N for the Pediatric Rheumatology Collaborative Study Group. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis. A double-blind, placebo-controlled pilot study. Clinical and Experimental Rheumatology 1995; 13:560. Abst #137.

21

Giannini EH, Ruperto N, Ravelli A, Shear ES, Tague BL, Murray K, Levinson JE, Martini A, Glass DN,. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. Clinical and Experimental Rheumatology 1996; 39:S56 Abst #138. Ruperto N, Levinson JE, Ravelli A, Shear ES, Tague BL, Murray K, Martini A, Giannini EH. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. Arthritis and Rheumatism 1996; 39:S56 Abst #180. Ruperto N, Ravelli A, Levinson JE, Shear ES, Murray K, Tague BL, Martini A, Glass DN, Giannini EH. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. II. Early predictors of outcome. Arthritis and Rheumatism 1996; 39:S56 Abstract #179. Murray KJ, Szer W, Grom AA, Donnelly P, Levinson JE, Glass DN, Szer I, Giannini EH. Antibodies to the 45 kDa nuclear antigen in pauciarticular onset JRA - Selective association with iridocyclitis and HLA-A2. Arthritis and Rheumatism 1996; 39:S315 Abstract #1720. Viola S, Ravelli A, Ruperto N, Villa I, Giannini EH, Martini A. Correlation between the clinical variables more commonly used for the assessment of articular involvement in juvenile rheumatoid arthritis. Arthritis and Rheumatism 1996; 39:S56 Abstract #178. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Martini A, for the Pediatric Rheumatology International Trials Organization. Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism 1996; 39:S56 Abstract #177. Giannini EH, Moroldo M. Paulus-like criteria perform well for describing improvement in juvenile arthritis. Arthritis and Rheumatism, 1997; 40(suppl):S243. Abstract #1272. Moroldo M, DeCunto C, Hübscher O, Russo R, Giannini EH. Cross-cultural adaptation and validation of the childhood HAQ for JRA in Argentina. Arthritis and Rheumatism, 1997; 40(suppl):S31. Abstract #2. Giannini EH, Moroldo M, Tague BL, Shear ES, Glass DN. Juvenile rheumatoid arthritis in affected sib-pairs. Arthritis and Rheumatism, 1997; 40(suppl):S243. Abstract #1272 Murray KJ, Donnelly P, Passo MH, Giannini EH, Glass DN. Windows of effect of disease associated HLA alleles in juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1997; 40(suppl):S241. Abstract #1261. Moroldo, MB, Saunders JR, Glass DN, Giannini, EH. Transmission test for linkage between HLA markers and genes that confer risk for JRA. Proc.Am.Acad.Pediatr Conference. Pediatric Rheumatology Into the Next Century. Park City, UT. 1998. Abstract No. 62. Lovell DJ, Giannini EH, Lange M, Soffes L, Finck BK for the Pediatric Rheumatology Collaborative Study Group. Tumor Necrosis Factor (P75) receptor Fc fusion protein, TNFR:FC, (EnbrelTM) in children with polyarticular course juvenile rheumatoid arthritis. Proc.Am.Acad.Pediatr Conference. Pediatric Rheumatology Into the Next Century. Park City, UT. 1998. Abstract No. S24.

22

Lovell DJ, Giannini EH, Whitmore JB, Soffes L, Finck BK for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of tumor necrosis factor receptor p75 Fc fusion protein (TNF:FC; EnbrelTM) in polyarticular course juvenile rheumatoid arthritis. Arthritis and Rheumatism 1998;41(suppl):S130. Abstract # 584.

Lovell DJ, Giannini EH, Lange M, Burge D, Finck BK. Safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis. Arthritis and Rheumatism 1999; Abstract #279. Thompson SD, Ryan M, Donnelly P, Binzler D, Groden J, Giannini EH, Glass DN. HLA and JRA: Linkage demonstrated by haplotype sharing in affected sib-pairs (ASPs). Arthritis and Rheumatism 1999; Abstract #687. Lovell DJ, Giannini EH, Lange M, Burge D, Finck for the Pediatric Rheumatology Collaborative Study Group.

Sustained safety and efficacy of Enbrel (etanercept) in the extended treatment of polyarticular course juvenile rheumatoid arthritis, Annals of Rheumatic Disease 2000; 59: 724. Abstract. Brunner HI, Lovell DJ, Giannini EH. Preliminary criteria for defining disease flare in patients with juvenile rheumatoid arthritis (JRA). Annals of Rheumatic Disease 2000; 59: 724. Abstract. Hicks J, Wesley R, Koziol D,…Giannini EH, … Rider L. Consensus and economic advantages in use of abbreviated manual muscle testing (MMT) in the assessment of idiopathic inflammatory myopathies (IIM). Arthritis and Rheumatism 2001; 44(suppl):S352. Abst. #1794. Ruperto N, Ravelli A, Murray KJ, Giannini EH, Lovell DJ….Martini A. International consensus for core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part I. Juvenile systemic lupus erythematosus (JSLE). Arthritis and Rheumatism 2001; 44(suppl):S261. Abst. # 1248. Ruperto N, Murray KJ, Ravelli, Lovell DJ, Giannini EH, …Martini A. International consensus for core sets of outcome measures for disease activity (DA) and disease damage (DD) assessment. Part II. Juvenile dermatomyositis (JDM). Arthritis and Rheumatism; 2001;44(suppl):S294. Abst. # 1446.

Brunner HI, Klein-Gitelman MS, Miller MJ…Giannini EH, Lovell DJ. The PEDSQL arthritis module can be used as core response variable (CRV) in children with juvenile rheumatoid arthritis (JRA). Arthritis and Rheumatism 2001; 44(suppl):S381. Abst. #1970. Prahalad S, Shear ES, Giannini EH, Glass DN. Increased prevalence of autoimmunity among relatives of patients with juvenile rheumatoid arthritis. Arthritis and Rheumatism 2001; 44:S167 Abst# 689. Bukulmez H, Thompson SD, Horn P, Giannini EH, Glass DN, Colbert RA. Tapasin polymorphism is associated with systemic onset juvenile rheumatoid arthritis (SoJRA). Arthritis and Rheumatism 2001; 44(suppl):S337. Abst. #1707. Giannini EH, Wallace CA, Brunner HI, for the Childhood Arthritis and Rheumatology Research Alliance. Barriers to participation in clinical research within the US pediatric rheumatology community. Arthritis and Rheumatism 2002; 46(suppl):S310 Abst #779.

23

Moroldo MB, Giannini EH, Shear ES, Thompson S, Glass DN: NIAMS – Juvenile rheumatoid arthritis affected sib-pairs registry. Arthritis and Rheumatism 2002; 46(suppl):S476 Abst # 1261. Rosen P, Moroldo MB, Lovell DJ, Thompson SD, Giannini EH, Glass DN: Discordant pnenotypes for methotrexate response in juvenile rheumatoid arthritis. Arthritis and Rheumatism 2002; 46(suppl):S470 Abst # 1243. Rider L, Giannini EH, Lovell DJ, et al for the International Myositis Outcome Assessment Collaborative Study Group. Defining clinically relevant change in core set activity measures for adult and juvenile idiopathic inflammatory myopathies (IIM). Arthritis and Rheumatism 2002; 46(suppl):S613 Abst # 1652. Giannini EH, Wallace CA, Brunner HI, for the Childhood Arthritis and Rheumatology Research Alliance. Barriers to participation in clinical research within the US pediatric rheumatology community. Pediatric Rheumatology Online Journal 2003 1(5): Abst #180 Giannini EH, Ruperto N, Tomasi AL, Gerloni V, Hafner R, Nielsen S, Pratsidou for the PRCSG and PRINTO: Neoral® registry in polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Online Journal 2003; 1(3): Abst #63. Giannini EH, Lovell DJ, Sherrard TM, Ilowite NT, Reiff A and the PRCSG. Etanercept/methotrexate registry in juvenile rheumatoid arthritis (JRA). Pediatric Rheumatology Online Journal 2003; 1(3): Abst #49 Lovell DJ, Giannini EH, Huang B, Ranz JV, Kramer SL and the PENTA Pediatric Rheumatology Group. Trial of calcium supplementation for bone mineralization in juvenile rheumatoid arthritis. Pediatric Rheumatology Online Journal 2003; 1(3):Abst #47. Rider LG, Giannini EH, Ruperto N, Reed A, Lachenbruch P, Miller F for the IMACS Group. Preliminary definitions of improvement for adult and juvenile myositis. Annals of Rheumatic Disease 2003; 62(suppl):32. Rider L, Giannini EH, Brunner H et al: Preliminary definitions of improvement for adult myositis. Arthritis and Rheumatism 2003; 48(suppl):S720. Rider L, Giannini EH, Brunner H et al: Preliminary definitions of improvement for juvenile myositis. Arthritis and Rheumatism 2003; 48(suppl):S433. Abst. #1079. Thompson SD, Moroldo MB, Guyer L, Ryan M, Tombragel E, Furlow S, Keddache M, Shear E, Brown M, Giannini EH, Langefield C, Rich S, Nichols WC, Glass DN. A genome wide screen in juvenile rheumatoid arthritis (JRA) affected sib-pair families. Arthritis and Rheumatism 2003; 48 (suppl);S255. Abst. # 578. Oddis C, Brunner H, Feldman B, Giannini EH, Koneru B, Miller F, Reed A, Ruperto N, Rider L, for the International Myositis Assessment and Clinical Studies (IMACS) Group. Development of consensus criteria for the conduct of clinical trials in adult and juvenile idiopathic inflammatory myopathy (IIM). Arthritis and Rheumatism 2003; 48(suppl);S3-8-9. Abst. #724. Ruperto N, Woo P, Cuttica R,... Giannini EH, Martini A, Pediatric Rheumatology International Trials Organisation (PRINTO). The validated PRINTO core set and definition of improvement for juvenile myositis. Clinical and Experimental Rheumatology 2004; 22:528

24

Lovell DJ, Giannini EH for the Pediatric Rheumatology Collaborative Study Group. Etanercept therapy in children with juvenile rheumatoid arthritis – 4 year outcome. Clinical and Experimental Rheumatology 2004; 22(4):522. Abst # 76. Giannini EH, Lovell DJ for the Pediatric Rheumatology Collaborative Study Group. Veith J, Tsuji W. Safety outcomes for etanercept therapy in children and adolescents with juvenile rheumatoid arthritis (JRA): Update from the pediatric registry. Clinical and Experimental Rheumatology 2004; 22(4):523. Abst. #82. Giannini EH, Lovell DJ, Illowite NT, Wallace CA, Schanberg LE for the Pediatric Rheumatology Collaborative Study Group, Veith J, Tsuji W. Safety Outcomes from a Phase IV Pediatric Registry: Etanercept (Enbrel®) Therapy in Children and Adolescents with Juvenile Rheumatoid Arthritis (JRA). Arthritis and Rheumatism 2004; 50(suppl):S90 Abst. #73. Lovell DJ, Reiff A, Jones OY, Schneider R, Giannini EH for the Pediatric Rheumatology Collaborative Study Group, Whitmore JB, White B. Long-term safety and efficacy experience with etanercept (Enbrel®) in children with polyarticular juvenile rheumatoid arthritis. Arthritis and Rheumatism 2004; 50(suppl):S436 Abst. # 1095. Lovell DJ, Ruperto N, Goodman S, Reiff A, Martini A, Giannini EH, Radin AR, Rao VS, Spencer-Green G. Preliminary Data from the Study of Adalimumab in children with juvenile idiopathic arthritis (JIA). Arthritis and Rheumatism 2004; 50(suppl): S436 Abst. # 1096. Ruperto N, Woo P, Cuttica R,... Giannini EH, Martini A, Pediatric Rheumatology International Trials Organisation (PRINTO). The validated PRINTO core set and definition of improvement for juvenile myositis. Arthritis and Rheumatism 2004; 50(suppl):S534 Abst. # 1389. Ruperto N, Lovell DJ, ….Giannini EH, Martini A for the the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients. Clinical and Experimental Rheumatology 2005;23(3):S-67 Ruperto N, DJ Lovell, ….EH Giannini, A Martini for PRINTO and the PRCSG Randomized Trial of Infliximab (IFX) plus Methotrexate (MTX) for the Treatment of Polyarticular Juvenile Rheumatoid Arthritis (JRA).Annals of Rheumatic Diseases 2005; 64(III):511 Lovell DJ,…Giannini EH: Comparison of safety, efficacy and pharmacokinetics for 3 and 6 mg/kg infliximab plus methotrexate therapy in JRA patients. Arthritis and Rheumatism 2005; 52(suppl):S724. Abst #1954. Visvananthan V,…..Giannini EH, …Wagner C. The effect of infliximab plus methotrexate therapy on the modulation of inflammatory disease markers in patients with juvenile rheumatoid arthritis. Arthritis and Rheumatism 2005; 52(suppl):S86. Abst.# 139. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff AA, Bevirt T, Chen C-Y, Tsuji WH. A phase IV registry of etanercept in children with juvenile rheumatoid arthritis. Annals of the Rheumatic Diseases 2006; 65(suppl 11):253-254.

25

Visvananthan V, Marini JC, Lovell DJ, Giannini EH, …Wagner C. Modulation of inflammatory disease markers after initiation of infliximab plus methotrexate therapy in patients with juvenile rheumatoid arthritis. Annals of the Rheumatic Diseases 2006; 65(suppl 11):467- 468. Lovell DJ, Giannini EH, Kimura Y, …Radin A. Preliminary evidence for bioactivity of IL-1 Trap (Rilonacept), A long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 2006; 65(suppl 11):693. Ruperto N, Lovell DJ, Goodman, S…..Giannini EH. 48 week data from the study of adalimumab in children with juvenile rheumatoid arthritis (JRA). Annals of the Rheumatic Diseases 2006; 65(suppl 11):56. Ruperto N, Lovell DJ, Prieur A-M…Giannini EH: Efficacy and safety of abatacept in children in and adolescents with active juvenile idiopathic arthritis (JRA). Annals of the Rheumatic Diseases 2006; 65(suppl 11):248 Lovell DJ, Giannini EH, Kimura Y et a: Preliminary evidence for bioactivity of IL-1 Trap (Riloncept), A long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (JIA). Accepted for publication, Arthritis and Rheumatism 2006; 54(suppl):S325. Abst. #718 Giannini EH, Ruperto N, Prieur A-M et al. Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of double-blind withdrawal phase. Arthritis and Rheumatism 2006; 54:4033. Abst#(482)L2. Lovell DJ, Ruperto N, Prieur A-M….Giannini EH, Martini A. Assessment of open-label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Arthritis and Rheumatism 2006; 54(suppl):S326. Abst #719. Lovell DJ, Ruperto N, Jung L….Giannini EH, Martini A. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results. Arthritis and Rheumatism 2006; 54(suppl):S303. Abst. #659. Block AJ, Ruperto N, Lovell DJ….Giannini EH, Martini A. Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA): Results of double-blind withdrawal phase. Rheumatology 2007; 46(suppl 1):i9-i10 Giannini EH, Ilowite NT, Lovell DJ, et al: The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis. Annals Rheumatic Disease 2007; 66(suppl II):550 Lovell DJ, Giannini EH, Wallace CA et al: Safety of over 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Annals Rheumatic Disease 2007; 66(suppl II):112 Ruperto N, Lovell DJ, Goodman S, Reiff….Martini A, Giannini EH. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Data over two years of treatment in a phase III trial. Annals Rheumatic Disease 2007; 66(suppl II):185

26

Ruperto N, Lovell DJ, Goodman S, Reiff A…Martini A, Giannini EH. Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing in the open-label (OLE) of a phase III study. Annals Rheumatic Disease 2007; 66(suppl II):185 Ruperto N, Giannini EH, Quartier P, et al: Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis after abatacept withdrawal and subsequent re-introduction. Annals Rheumatic Disease 2007; 66(suppl II):436 Ruperto N, Giannini EH, Prieur A-M et al: Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis: Results of double-blind withdrawal phase. Annals Rheumatic Disease 2007; 66(suppl II):87 Ruperto N, Lovell DJ,…Giannini EH: Two-year efficacy of adalimumab in children with juvenile rheumatoid arthritis (JRA): Results of a Phase III trial. Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007:84 Abst. OP-29 Ruperto N, Giannini EH, Prieur A-M et al: Efficacy and safety of abatacept in children and adolescents with active juvenile idiopathic arthritis: Results of double-blind withdrawal phase. Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007: 82-83 Abst. OP-28 Lovell DJ, Giannini EH, et al: Preliminary evidence for sustained bioactivity of IL-1 Trap (Rilonocept), a long acting IL-1 inhibitor in systemic juvenile rheumatoid arthritis. Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007: 86. Abst #OP-31 Ruperto N, Giannini EH, Quartier P, et al: Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis after abatacept withdrawal and subsequent re-introduction. Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007: 166. Abst# PP-61 Giannini EH, Ilowite NT, Lovell DJ, et al: The long-term safety of etanercept in children with polyarticular or systemic juvenile rheumatoid arthritis. Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007: 81 Abst. OP-27 Sobel RE, Lovell, DJ, Giannini EH, Sheth N, Abramsky S, Cawkwell G. A new multicenter registry to monitor long-term safety of non-steroidal anti-inflammatory drugs (NSAIDs) including Celebrex in juvenile idiopathic arthritis (JIA). Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007: 193. Abst# PP-84 Lovell DJ, Giannini EH, Wallace CA, et al: Safety and efficacy of over 8 years of continuous etanercept (Enbrel) therapy in patients with juvenile rheumatoid arthritis. Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007: 229. Abst # PP-116 Ruperto N, Lovell DJ…Giannini EH: Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): Converting from body surface area dosing to fixed dosing. Proceeding of the 14th Pediatric Rheumatology European Society Rheumatology Congress 2007: 176. Abst# PP-69

27

Giannini EH, Ruperto N, Prieur A-M et al: Efficacy of abatacept in different sub-populations of juvenile idiopathic arthritis. Results from a double-blind trial. Arthritis and Rheumatism 2007; 56 (suppl): S291. Abst #679 Lovell DJ, ….Giannini EH, Martini A: Abatacept treatment of juvenile idiopathic arthritis: safety report. Arthritis and Rheumatism 2007; 56 (suppl): S292. Abst #680 Lovell DJ…Giannini EH, Martini A: Adalimumab is safe and effective during long-term treatment of patients with juvenile rheumatoid arthritis. Results from a 2 year study. Arthritis and Rheumatism 2007; 56 (suppl): S292. Abst #681 Reiff AO, Giannini EH: Safety and Efficacy of over 8 years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis and Rheumatism 2007; 56 (suppl): S292-3. Abst #682 Lovell DJ…Giannini EH, Martini A: Adalimumab for the treatment of patients with juvenile rheumatoid arthritis: safety and efficacy after conversion from body-surface-area dosing to weight-based fixed dosing. Arthritis and Rheumatism 2007; 56 (suppl): S373-4. Abst #895 Gordon KB, Gottlieb AB, Giannini EH et al: Clinical trial safety data of events of interest in patients receiving etanercept across approved indications. Arthritis and Rheumatism 2007; 56 (suppl): S399-400. Abst #960 Lovell DJ, Giannini EH, et al: Preliminary evidence for sustained bioactivity of IL-1 Trap (Rilonocept), a long acting IL-1 inhibitor in systemic juvenile rheumatoid arthritis. Arthritis and Rheumatism 2007; 56 (suppl): S514-5. Abst #1282 Khana D, Lovell DJ, Giannini EH et al: Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Arthritis and Rheumatism 2007; 56 (suppl): S8123-4 Abst #2162 Gordon KB, Gottlieb AB, Giannini EH Mease PJ: Clinical trial safety data of events of interest in patients receiving etanercept (ENBREL) across approved indications. Journal of the American Academy of Dermatology 2008; 58(2) suppl 2: AB120, abst # P2610 Giannini EH, Marsden, Berger, van der Ploeg, Case, Dandrea, Kishmani. Disease methods: Development of a simple mechanism to calculate disease severity in Pompe patients. Neuromuscular Disorders, 2008 Giannini EH, Berger K, van der Ploeg et al: Development of a disease severity scoring system for patients with Pompe disease. Proc Society for Inherited Metabolic Diseases, 2008. Davies EH, Giannini EH: A severity scoring tool for neuronopathic Gaucher disease – weighing the domains. Molecular Genetics and Metabolism 2008; 93:S18. Abst #20. Giannini EH, Wilcox W for the Anderson-Fabry disease DS3 Working Group. Development of a disease severity scoring system for Anderson-Fabry disease. Molecular Genetics and Metabolism 2008; 93:S22. Abst # 32.

28

Marsden D, Berger K, van der Ploeg A, Case L, Dandrea C, Kishnani P, Giannini EH: Development of a disease severity scoring system for patients with Pompe disease. Molecular Genetics and Metabolism 2008; 93:S66. Abst # 66. Zimran A, Cappellini M, Cox Timothy, Giannini EH et al: Development of a disease scoring system for Type I Gaucher disease. Molecular Genetics and Metabolism 2008; 93:S45. Abst #117. Wallace CA, Lovell DJ, Giannini EH, Hamilton SW, Johnson AL: Interim report of the Trial of early aggressive therapy (TREAT) in JIA study. Proc Am Coll Rheum Keystone Pediatric Rheumatology Symposium, Keystone, CO. 2008; Abst #3 Reiff AO, Lovell DJ, Ilowite NT, Wallace CA, Chon Y, Lin S-L, Baumgartner SW, Giannini EH: Safety and efficacy of over 8 years of continuous etanercept (Enbrel®) therapy in patients with juvenile rheumatoid arthritis. . Proc Am Coll Rheum Keystone Pediatric Rheumatology Symposium, Keystone, CO. 2008; Abst #4 Lovell DJ, Bowyer, S, Colbert RA, Giannini EH, et al: Progress in identification of quality measures for juvenile idiopathic arthritis. Proc Am Coll Rheum Keystone Pediatric Rheumatology Symposium, Keystone, CO. 2008; Abst #69 Giannini EH, Ilowite NT, Lovell DJ, et al: The long-term safety of etanercept (Enbrel®) in children with polyarticular or systemic juvenile rheumatoid arthritis. Proc Am Coll Rheum Keystone Pediatric Rheumatology Symposium, Keystone, CO. 2008; Abst #83 Ruperto N, Quartier P, Giannini EH, et al: Clinical benefit is re-established with the reintroduction of abatacept following a 6-month withdrawal period in patients with juvenile idiopathic arthritis. British Society of Rheumatology, 2008 Ruperto N, Quartier, P….Giannini EH, Martini A: Abatacept is well tolerated in a double-blind randomized withdrawal study, with an open-label extension, in patients with juvenile idiopathic arthritis. British Society of Rheumatology, 2008. Ruperto N, Lovell DJ, Cuttica R…Martini A, Giannini EH for PRINTO and PRCSG: Lon-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension.Pediatric Rheumatology 2008; 6 (suppl 1):S3 Ruperto N, Lovell DJ, Li T, Quartier P, Chavez J, Huemer C, Kivitz A, Blanco F, Foeldvari I, Hofer M, Sigal L, Block A, Covucci A, Martini A, Giannini EH: Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients. Pediatric Rheumatology 2008; 6 (suppl 1):P85 Giannini EH, Berger K, van der Ploeg, et al: Development of a disease severity scoring system for patients with Pompe disease. Third International Congress of Myology, Paris, 2008 Giannini EH et al: Progress in development and testing of reliability and validity of a disease severity scoring system (DS3) for Anderson-Fabry Disease. Proc American College of Medical Genetics, Phoenix, 2008

29

Gottlieb AB, Gordon KB, Giannini EH, et al: Malignancies from patients receiving etanercept across approved indications. EULAR, 2008 Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Baumgartner SW, Lin S-L: Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis. Pediatric Rheumatology 2008; 6 (suppl 1): S15 Sobel R, Lovell D, Giannini EH, et al: SINCERE™: A new multicenter registry to monitor long-term safety of nonsteroidal anti-inflammatory drugs (NSAIDs) including celecoxib in juvenile idiopathic arthritis (JIA). Proc Internatl Soc Pharmacoepidemiology (ISPE) Aug, 2008. Fury W…Giannini EH, Kivitz AJ, Yancoppoulos GD, Mellis SJ: Whole blood gene expression profiling of cryopyrin associated periodic syndromes and systemic juvenile idiopathic arthritis subjects treated with rilonacept. Arthritis and Rheumatism 2008; 58 (suppl): S218-9. Abst #139 Sandborg C, Giannini EH, et al: Consensus development of a corticosteroid (CS) tapering algorithm for the randomized placebo phase study of rilonocept in the treatment of systemic JIA ( Rapport). Arthritis and Rheumatism 2008; 58 (suppl): S248-9. Abst #219 Lovell DJ, Ruperto N…Giannini EH, et al: Responses are maintained for up to 3 years of adalimumab treatment in polyarticular juvenile idiopathic arthritis. Arthritis and Rheumatism 2008; 58 (suppl): S609-10. Abst #1187 Lovell DJ, Ruperto N…Giannini EH, Martini A: Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients. Arthritis and Rheumatism 2008; 58 (suppl): S625. Abst #1226 Ruperto N, Lovell DJ, Li T, Paz E, Horneff G, Huppertz HI, Deslandre HI, Minden K, Punaro M, Nunez AF, Sigal L, Block A, Martini A, Giannini EH: Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept. Pediatric Rheumatology 2008; 6(suppl 1) P86 Lovell DJ, Ruperto N…Giannini EH, Martini A: Long-term efficacy & safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Arthritis and Rheumatism 2008; 58 (suppl): S632. Abst #1246 Giannini EH, Ilowite NT, et al: Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis. Arthritis and Rheumatism 2008; 58 (suppl): S719-20. Abst #219 Li T, Lovell DJ…Giannini EH, Covucci A, Martini A: Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept. Arthritis and Rheumatism 2008; 58 (suppl): S2909. Abst #2019 Giannini EH: Children with chronic diseases and particular needs in health care. Trends, magnitude and scope of the problem. Proc 44th Chilean Pediatric Society, Viña del Mar, Chile, 2008.

30

Giannini EH: Ethical and practical issues in care of children with chronic diseases. Proc 44th Chilean Pediatric Society, Viña del Mar, Chile, 2008. Giannini EH: Quality of life in children with chronic diseases and their families. Concepts, evaluation and experience. Proc 44th Chilean Pediatric Society, Viña del Mar, Chile, 2008. Giannini EH: Practical management of children with particular needs in health care. Proc 44th Chilean Pediatric Society, Viña del Mar, Chile, 2008. Zimran A, Cappellini M, Cox T, Giannini EH, et al: Development of a disease severity scoring system for Type 1 Gaucher Disease. Proc American College of Medical Genetics, Phoenix, 2009 Hashkes, PJ Daniel L. Lovell, Giannini EH, Huang B, Kastner DL: Rilonacept (IL-1 Trap) for Treatment of Colchicine Resistant Familial Mediterranean Fever: A Randomized, Multicenter Double-Blinded, Alternating Treatment (N of 1) Trial. Clinical and Experimental Rheumatology, 2009

Hashkes PJ, Kastner DL, Huang B, Giannini EH, Lovell DJ: The study design of IL-1 Trap for treatment of Familial Mediterranean Fever (FMF) as a template for studying rare orphan diseases. Clinical and Experimental Rheumatology, 2009 Ruperto N, Lovell DJ, Mouy R…Giannini EH: Long-term safety and efficacy of abatacept in subjects with polyarticular juvenile idiopathic arthritis. Proc German Congress of Rheumatology 2009, Cologne. Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, …Ales Linhart: A validated disease severity scoring system for Fabry disease. Proc Fabry Disease Round Table, Prague, 2009 Giannini EH, Ilowite N, Lovell DJ, Wallace CA, Rabinovich E, Reiff A, Higgins G, Gottlieb B, Chon Y, Baumgartner. Effects of long-term treatment with etanercept on growth in children with polyarticular course or systemic juvenile rheumatoid arthritis. Annals of the Rheumatic Diseases 2009; 68(suppl 3):308. N. Ruperto, D. J. Lovell, R. Mouy, E. Paz, N. Rubio-Perez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas1, V. Gerloni, J. A. Melo-Gomes, C. Saad-Magalhaes, J. Chavez, C. Huemer, A. Kivitz, F. Blanco, I. Foeldvari, . Hofer, G. Horneff, H. Huppertz, C. Job Deslandre, K. Minden, M. Punaro, A. Flores Nunez, L. H. Sigal, A. J. Block, A. Covucci, A. Martini, E. H. Giannini. Long-term safety and efficacy of abatacept in subjects with polyarticular juvenile idiopathic arthritis (JIA). Proc Société Française de Rhumatologie Congress, Paris, 2009 Wallace CA, Giannini EH, Ruperto N, for CARRA, PRCSG and PRINTO networks. Optimization of the provisional criteria for clinically inactive disease for select categories of juvenile idiopathic arthritis. Arthritis and Rheumatism 2009; 60 (10) suppl: S749 (abst #2004) Lovell DJ, Giannini EH, Kimura Y, et al: Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (sJIA). Arthritis and Rheumatism 2009; 60 (10) suppl: S768 (abst #2053)

31

Waldek S, Giannini E, Mehta A, Hilz M, Beck M, Bichet D, Brady R, West M, Germain D, Wanner C, Clarke J, Warnock D, Linhart A. A validated disease severity scoring system for Fabry disease. Molecular Genetics and Metabolism 2010; 99(2):S37 (abst #140) Hashkes PJ, Spalding SJ, Lovell DJ, Giannini EH, Huang B, Kastner D: Rilonacept (IL1-Trap) for treatment of colchicine resistant familial Mediterranean fever. A randomized, multicenter double-blinded, alternating treatment (N of 1) trial. Proc Autoinflammatory meeting, Apr 2010. Hashkes PJ, Huang B, Lovell DJ, Giannini EH, Park G, Weiss MH, Pashinian N, Reiff AO, Samuels J, Wright D, Kastner DJ, Spalding SJ. Health related quality of life of a Familiar Mediterranean Fever cohort with severe disease due to colchicine resistance or intolerance. Proc Autoinflammatory Meeting, Apr 2010. Visvanathan S, Wagner C, Marini JC, …Giannini EH, Ruperto N, for the PRINTO and PRCSG. The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo controlled trial. Pediatric Rheumatology 2010; 8:24 Ruperto N, Lovell DJ, Reiff A, Higgins G, Kone-Paut I, Jones O, Chalom E, Ilowite N, Wouters C, McIlraith MJ, Liu S, Kupper H, Giannini EH, Martini A. Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis. Pediatric Rheumatology 2011; 9(suppl 1):O26 Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Park G, Barron KS, Weisman MH, Pashinian N, Reiff AO, Samuels J, Wright D, Kastner DL, Lovell DJ. Rilonacept (IL-1 Trap) for treatment of colchicine resistant familial Mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial. Pediatric Rheumatology 2011; 9 (suppl 1):O38 Lovell DJ, Ruperto N, …Giannini EH, Peterson T, Martini A: Long-term efficacy and safety of adalimumab for up to 6 years in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism 2011; 63(10) Suppl:S99, Abst #265. Wallace CA, Giannini EH….Lovell DJ. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis and Rheumatism 2011; 63(10) Suppl:S281, Abst #721. Hashkes PJ, Spalding SJ, Giannini EH…Lovell DJ: Rilonacept (Interleukin-1 Trap) for treatment of colchicine resistant familial Mediterranean fever. Arthritis and Rheumatism 2011; 63 (10) Suppl:S952, Abst #2445. Mina R, Schanberg LE, Klein-Gitelman M,…Giannini EH, Brunner HI: Defining clinical remission and inactive disease in juvenile systemic lupus erythematosus. Arthritis and Rheumatism 2011: 63(10) Suppl:S956, Abst #2454. Thapa M, Spalding SJ, Hashkes PJ, Ringold S, Zeft AS, Sundel RP, Otto RK, Giannini EH, Lovell DJ, Wallace CA: MRI findings from the trial of early aggressive therapy (TREAT) study. Pediatric Rheumatology 2012; 10 (suppl 1):A36 Lovell DJ, Spalding SP, Onel K, Gottlieb BS, Brunner HI, Kimura Y, Morris PW, Olson JC, Johnson A, Giannini EH: Understanding the biology and use of anti-TNF agents in juvenile idiopathic arthritis – Interim results. Pediatric Rheumatology 2012; 10(suppl 1):A48

32

Wallace CA, Giannini EH, Spalding S…Lovell DJ: The effects of early aggressive therapy in JIA: results of the TREAT study. Pediatric Rheumatology 2012; 10 (suppl 1):A56 Sobel R, Lovell DJ, Brunner HI…Giannini EH: Safety of celecoxib and non-selective non-steroidal anti-inflammatory drugs in juvenile idiopathic arthritis: Results of the phase IV registry. Arthritis and Rheumatism, Accepted for publication, 2012 Lovell DJ, Ruperto N, Jarosova K, …Giannini EH, Martini A, Mozaffarian N: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, Accepted for publication, 2012 Huang B, Giannini EH, Hashkes PJ. Early escape per patient-choice to the alternative treatment in a cross-over double-blind, placebo-controlled trial of a rare disease: Design and analytical considerations. Proc Conference on Clinical Research for Rare Diseases, Oct 2012, Rockville, MD Abst #21. Letters to the Editor: van Kerckhove C, Lovell DJ, Giannini EH: Letter of Reply, Arthritis and Rheumatism 1989; 32:1185-1186. Sheerin KA, Barron KS, Giannini EH, Brewer EJ Jr,: Outcome of B27 positive children. Letter of Reply. Arthritis and Rheumatism 1989; 32:1054-1055. Giannini EH, Brewer EJ: Auranofin in JRA. Letter of Reply. Arthritis and Rheumatism 1991; 34:935. Giannini EH, Brewer EJ: Methotrexate for Juvenile Rheumatoid Arthritis. Letter of Reply. New England Journal of Medicine 1992; 327:893-894 Lovell DJ, Giannini EH. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis - preliminary results of a long-term study. - Reply. Journal of Rheumatology 1993; 20:593-594. Gedalia A, Giannini EH, Brewer EJ, Person DA: Prevalence of pericardial effusion by echocardiography in juvenile rheumatoid arthritis. Journal of Rheumatology 1993; 20:206-207. Giannini EH, Ruperto N. Clinically important change in treatment trials for juvenile rheumatoid arthritis. Letter of reply Journal of Rheumatology 1997, 24:610. Feldman BM, Giannini EH. Pediatric Rheumatology in the 21st century. Letter of reply. Journal of Rheumatology 1997; 24:1856. Lovell DJ, Passo MH, Giannini EH, Brunner H. Systemic onset juvenile idiopathic arthritis: A retrospective study of 80 consecutive patients followed for 10 years. Journal of Rheumatology 2001; 28:220. Ruperto N, Martini A, Lovell DJ, Giannini EH: Performing trials in children with rheumatic diseases: comment on the editorial by Lehman. Arthritis and Rheumatism 2008; 58:1201-1202.

33

Lovell DJ, Henrickson M, Morgan DeWitt E, Segerman J, Taylor J, Giannini EH…Vehe R: Letter of reply: Measuring process of arthritis care: A proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care and Research 2011, 63:1353. Updated Oct 2012.